Physician profile
William Rayburn
NPI 1922015999
$1,306.71
in general payments reported to CMS, 2019-2025
14 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $356 · 2021: $400 · 2022: $181 · 2023: $95.87 · 2024: $26.64 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $316.09 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $230.10 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $175.14 | 2020-2021 | |
| Abbvie INC. | $119.73 | 2021-2023 | |
| Corium, LLC | $118.54 | 2022 | |
| Bausch Health US, LLC | $78.92 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $49.97 | 2021-2022 | |
| Neos Therapeutics, LP | $49.12 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.86 | 2020-2021 | |
| Eisai INC. | $37.28 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.64 | 2024 | Cobenfy |
| Janssen Scientific Affairs, LLC | $23.31 | 2021 | |
| Lundbeck LLC | $21.30 | 2020 | |
| Alfasigma USA, INC. | $11.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rayburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.